2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
74
Hodgkin Disease
56
Lymphoma
22
Sarcoma
13
Neoplasm Metastasis
11
Leiomyosarcoma
8
Uveal Melanoma
7
Neoplasms
7
Skin Neoplasms
6
Neuroblastoma
4
Sarcoma, Synovial
3
Recurrence
3
Solitary Fibrous Tumors
2
Sarcoma, Alveolar Soft Part
2
Hematologic Diseases
2
HIV Infections
2
Thyroid Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Melanoma, Cutaneous Malignant
1
Melanoma Neoplasms
1
Interventions
Diathermy
22
Radiotherapy
11
Drug Therapy
5
Cisplatin
5
Fluorouracil
4
Radiation
3
Melphalan
3
Immune Checkpoint Inhibitors
3
Cytoreduction Surgical Procedures
3
Brachytherapy
3
tislelizumab
2
Surgical Procedures, Operative
2
Solutions
2
Immunotherapy
2
Hyperthermia, Induced
2
Hydrogen Peroxide
2
Doxorubicin
2
Conization
2
Capecitabine
2
spartalizumab
1
sodium thiosulfate
1
anlotinib
1
Therapeutics
1
Temozolomide
1
Saline Solution
1
Radiation Dose Hypofractionation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Mitomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hyperthermia
×
Dacarbazine
×
Clear all
NCT06835049
2025-12-30
TNT-HYPE
Swiss Cancer Institute
Phase 2
Recruiting
24 enrolled